🇺🇸 FDA
Pipeline program

Eliglustat, Cerezyme 400 Units Powder for concentrate for solution for infusion, Cerezyme 400 Units Powder for concentrate for solution for infusion, Eliglustat, Eliglustat, Cerezyme 400 Units Powder for concentrate for solution for infusion, Eliglustat

EFC13738

Phase 3 small_molecule active

Quick answer

Eliglustat, Cerezyme 400 Units Powder for concentrate for solution for infusion, Cerezyme 400 Units Powder for concentrate for solution for infusion, Eliglustat, Eliglustat, Cerezyme 400 Units Powder for concentrate for solution for infusion, Eliglustat for Gaucher's disease type I; Gaucher's disease type III is a Phase 3 program (small_molecule) at Genzyme Europe B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Genzyme Europe B.V.
Indication
Gaucher's disease type I; Gaucher's disease type III
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials